An observational study in Thrombosis, Blood Coagulation Disorder and Platelet Thrombus, sponsored by Scientific Institute San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Scientific Institute San Raffaele · Observational
Consenting patients with end-stage heart failure that are implanted with/candidates for implant of a short-term/durable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane oxygenator (ECMO), Ventricular Assist Device (VAD) will be enrolled in the study.
Aim of the study is to evaluate the patients' haemostatic and coagulation profile, how it interacts with the support device as well as the effect of antithrombotic drugs. From these data, it will be possible to derive the mechanisms triggering post-implant thromboembolic/hemorrhagic complications and to identify potential therapeutic targets.
The study is aimed at evaluating the patients' haemostatic and coagulation profile focusing, in particular, on platelet function. Platelet function will be analyzed utilizing two innovative analytic diagnostic tests, namely i) the Platelet Activity State (PAS) assay and ii) the Thrombin Generation Test (TGT).
PAS values and TGT will be measured at different time-points over the course of support:
i) before the implant of the support system, to define baseline patients' characteristics; ii) in the early-post implant, during patient hospitalization; iii) during long-term follow up, to evaluate the dynamics of platelet function over the course of support and potential alterations of platelet-mediated haemostatic processes; iv) at the occurrence of any thromboembolic/hemorrhagic complication or following a modification of the antithrombotic pharmacological therapy.
Platelet function will be evaluated through:
i) the Platelet Activity State (PAS) assay, a biochemical assay able to quantify the platelet thrombin production rate and to correlate this rate with the actual level of platelet activation (i.e., the platelet pro-thrombotic tendency); ii) the Thrombin Generation Test (TGT), a biochemical assay that the investigators have properly modified to account selectively for the platelet contribution on plasmatic thrombin generation.
PAS and TGT experimental values will be correlated with the occurrences of post-implant complications. Experimental values will be also correlated with standard clinical parameters of coagulation and hemolysis, such as: platelet count, hematocrit, hemoglobin, prothrombin time (PT), activated partial thromboplastin time (aPTT), International Normalized Ratio (INR), D-Dimer, Fibrinogen, L-lactate dehydrogenase, haptoglobin, plasma-free hemoglobin, and C-reactive protein levels. Also levels of thrombin-antithrombin complex, Von Willebrand factor, prothrombin1,2 fraction and tissue factor, will be measured and recorded. In addition, pump (i.e. VAD) working parameters (i.e., rotation velocity, cardiac outflow and power consumption) will be recorded. Log-files of the pump will be downloaded and analyzed to characterize the correlation with the development of adverse events (AV). Finally, antithrombotic therapy will be recorded and used in the study.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 60 is below the median of 173 across 384 observational studies indexed under Thrombosis.
Browse Thrombosis studies →Scientific Institute San Raffaele is the lead sponsor of 29 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with end-stage heart failure receiving a mechanical circulatory support system
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients receiving a VAD implant
Diagnostic Test: PAS assay, TGT
VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
Diagnostic Test: PAS assay, TGT
Evaluation of platelet function
Number of participants with treatment-related adverse events. Change of PAS assay from baseline to 24 months post-implant
Correlation between platelet activation and the development of post-implant complications
Time frame: Through study completion. Specific time-points: 1, 3, 6, 12, 18, and 24 months post-implant and at the occurrence of any AE
Number of participants with treatment-related adverse events. Change of TGT from baseline to 24-months post-implant
Correlation between platelet pro-thrombinase activity and the development of post-implant complications
Time frame: Through study completion. Specific time-points: 1, 3, 6, 12, 18, and 24 months post-implant and at the occurrence of any AE
Number of participants with treatment-related adverse events. Change of clinical and coagulation parameters from baseline to 24-months post-implant
Correlation between coagulation parameters and the development of post-implant complications
Time frame: Through study completion. Specific time-points: 1, 3, 6, 12, 18, and 24 months post-implant and at the occurrence of any AE
Number of participants with treatment-related adverse events. Change of pump working conditions after the device implant
Correlation between pump working conditions and the development of post-implant complications
Time frame: Through study completion. Specific time-points: 1, 3, 6, 12, 18, and 24 months post-implant and at the occurrence of any AE
Number of participants with treatment-related adverse events. Change of prescribed antithrombotic therapy (anticoagulation and antiplatelet drugs) from baseline to 24 months post-implant
Correlation between antithrombotic therapy and the development of post-implant complications
Time frame: Through study completion. Specific time-points: 1, 3, 6, 12, 18, and 24 months post-implant and at the occurrence of any AE
Plan to share: No — Privacy restrictions
Started Jun 2017 (actual). Primary completion is estimated for Dec 2026, 114 months after the start.
Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 114 months is above that.
Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scientific Institute San Raffaele